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Abstract
Introduction: Hepatocyte transforming factor 1B-maturity onset diabetes mellitus of the young (HNF1B-MODY) is an autosomal dominant 
type of monogenic diabetes caused by a mutation in the gene encoding hepatocyte nuclear factor 1beta (HNF-1beta). 
The aim of this study was to determine if a HNF1B gene mutation was responsible for a dominantly inherited form of diabetes mellitus 
among the members of a three-generation Polish family. 
Material and methods: The index subject was a 13-year-old boy with metabolic syndrome, spina bifida occulta, posterior urethral valves, 
congenital ureteropelvic junction obstruction, and a family history of diabetes of autosomal dominant trait of inheritance. We performed 
clinical and laboratory examinations of his family and sequenced the HNF1B gene. 
Results: A novel Q248X mutation (nucleotide C to T transition at position 742 of the exon 3 of HNF1B gene, resulting in stop codon forma-
tion) was identified. Phenotypes of family members sharing this mutation are highly variable, and include previously known abnormali-
ties of the urinary system and pancreas, diabetes mellitus of variable onset and severity, hyperinsulinaemia, insulin resistance, metabolic 
syndrome, elevated aminotransferases, hyperbilirubinemia, hyperamylasemia, short stature and cataracts. To the best of our knowledge, 
spina bifida occulta, pectus carinatum, and splenomegaly have not been previously reported.
Conclusions: Our results broaden the spectrum of HNF1B gene mutations and HNF1B-MODY-related phenotypes. 
(Endokrynol Pol 2015; 66 (1): 15–21)
Key words: hepatocyte nuclear factor 1-beta; HNF1B-MODY; pectus carinatum; phenotype; spina bifida occulta; splenomegaly; Q248X 
mutation
Streszczenie
Wstęp: Cukrzyca HNF1B-MODY dziedziczona w sposób autosomalnie dominujący jest rodzajem cukrzycy monogenowej, którą po-
woduje mutacja w genie HNF1B (hepatocyte transforming factor 1B). Celem pracy było zbadanie czy mutacja w HNF1B jest przyczyną 
występowania cukrzycy w trzech pokoleniach polskiej rodziny. 
Materiał i metody: Przeprowadzono ocenę kliniczną i laboratoryjną oraz sekwencjonowanie genu HNF1B trzynastoletniego chłopca 
z zespołem metabolicznym, rozszczepem kręgosłupa, zastawkami cewki tylnej i wrodzonym zwężeniem moczowodu oraz obciążonym 
wywiadem rodzinnym w kierunku cukrzycy. Ze względu na wywiad rodzinny o autosomalnie dominującym sposobie dziedziczenia 
cukrzycy zbadano również członków jego rodziny. 
Wyniki: Stwierdzono obecność nowej mutacji Q248X będącej skutkiem przeniesienia nukleotydu C na miejsce T w pozycji 742 eksonu 
3 genu HNF1B i powstaniem kodonu stop. Cechy fenotypowe członków rodziny będących nosicielami tej mutacji okazały być się bardzo 
zróżnicowane, a niektóre z nich takie jak spina bifida occulta, pectus carinatum i splenomegalia nie były dotychczas opisywane. 
Wnioski: Wyniki poszerzają spectrum mutacji genu HNF1B oraz związanych z nimi cech fenotypowych cukrzycy HNF1B-MODY .
(Endokrynol Pol 2015; 66 (1): 15–21)
Słowa kluczowe: hepatocytowy czynnik jądrowy 1-beta; HNF1B-MODY; pectus carinatum; fenotyp; spina bifida occulta; splenomegalia; 
Q248X mutacja
This work was funded from the Innovative Economy Operational Programme — Activity 1.2 — the TEAM Project: Polish Registry for Paediatric 
and Adolescent Diabetes — nationwide genetic screen for monogenic diabetes, coordinated by the Foundation for Polish Science and by 
National Science Centre grant number 2011/01/D/NZ5/02811, entitled: ‘Bioinformatics-driven search for molecular markers of HNF1B related 
phenotypes of diabetes and renal anomalies’.
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Diabetes Autoantibody Standardisation Programme 
(DASP) 2010, the disease sensitivity of the ICA, GADA, 
and IA2A was 69.4%, 88% and 70% respectively, while 
the corresponding specificities were 93.3%, 94.4% and 
83.3%.
Mutation detection
Genomic DNA was isolated from peripheral blood 
leukocytes using QiaAmp DNA mini kits from Qiagen 
(Qiagen, Hilden, Germany) in accordance with the 
manufacturer ’s instructions. DNA sequences of the 
HNF1B region were amplified by means of PCR reaction 
[2]. Products were evaluated by means of 2% agarose gel 
electrophoresis with ethidium bromide. Results were 
analysed and stored as digital UV photographs. DNA 
purification was performed using Qiaquick columns 
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. DNA sequencing was performed 
using BigDye Seq kit v3.1 (Applied Biosystems, Foster 
City, CA, USA). Sequencing reaction was conducted 
by using 200 ng of PCR product as a matrix in a label-
ling reaction, 50pM of one oligonucleotide (forward 
and reverse, separately) and 2.5x sequencing buffer. 
Sequencing reactions were conducted under the fol-
lowing protocol: 15 sec. at 95°C, 36 replications of: 95°C 
20 sec., 60°C 5 sec. and 61°C 4 min. After the sequencing 
reaction, the products were precipitated with 125 mM 
EDTA, 3M sodium acetate and 96% ethanol. The vials 
were centrifuged for 45 min. at 8,000 rpm, kept dry at 
room temperature afterwards, and resolved in HiDi 
Formamide (Applied Biosystems).
The identification of mutations was performed by 
direct sequencing using the ABI 3130 genetic analyser 
(Applied Biosystems). Analysis of chromatograms was 
performed using DNA Sequencing Analysis Software 
(Applied Biosystems). For comparative analysis of 
evaluated sequences with the human genome reference 
(RefSeq NM_000162.3), the Sequencher software v4.1.4 
(GeneCodes, Ann Arbor, MI, USA) was used.
This study was approved by the Bioethics Commit-
tee of the Medical University of Lodz, Poland. Informed 
consent was obtained from all patients / parents.
Results
Phenotypic variability among family members
Proband
On admission, the boy’s height was 174 cm (97th cen-
tile) and weight 72 kg. The BMI (body mass index) of 
23.8 kg/m2 indicated overweight (BMI-for-age at the 
92nd percentile for boys aged 13 years 1 month, Z-Score 
1.41). His blood pressure was increased (average 150/110 
mmHg). Laboratory analyses showed fasting hypergly-
Introduction
HNF1B-MODY is one of the most rarely diagnosed 
types of diabetes, affecting 0.6% of children and adoles-
cents with all forms of diabetes mellitus. It accounts for 
4.7% in subjects with auto-antibody-negative diabetes 
and 11% in a subgroup of those with genetic testing for 
a monogenic form of diabetes called MODY (maturity 
onset diabetes in the young) [1]. It was first described 
in 1997 in a Japanese family as the association of early-
onset diabetes and non-diabetic nephropathy [2]. Due 
to its rarity, detailed scientific information about geno-
type/phenotype correlation is still very limited.
HNF1B-MODY results from a mutation in the 
gene encoding HNF1-beta (hepatocyte nuclear factor 
1-beta, also known as vHNF1 or TCF2), a widely dis-
tributed transcription factor which forms an integrated 
regulatory network with other transcription factors [3]. 
HNF1-beta is expressed in many organs including the 
pancreas, liver, lung and thymus, as well as the gastro-
intestinal and genitourinary tracts, and plays a critical 
role in early development and embryonic survival [4, 5]. 
Therefore, HNF1B-MODY has a wide clinical spectrum 
including the most common features such as diabetes, 
nondiabetic renal disease, congenital malformations 
and dysfunction of the above mentioned organs [1]. 
Here we present a three-generation family diag-
nosed with HNF1B-MODY caused by a novel nonsense 
mutation in the HNF1B gene.
Material and methods
Subjects
The index subject (III-1) was a 13-year-old boy referred 
to hospital due to fasting hyperglycaemia (7.2–7.8 
mmol/L), increased blood pressure, and tachycardia. 
He was born on the due date with a birth weight of 
2,900 g and with asymptomatic spina bifida occulta of 
the lumbo-sacral region. In the first month of his life, 
he was diagnosed with posterior urethral valves and 
underwent surgical treatment. At nine months of age, 
he was operated on again due to congenital uretero-
pelvic junction obstruction. The family history revealed 
that his father, father’s brother and grandmother (the 
father’s and uncle’s mother) also suffered from diabetes.
Autoantibodies detection
The conventional autoantibodies were measured on 
serum samples: ICA with immunofluorescence, an-
tibodies against GAD and IA2 by ELISA (RSR, USA), 
and insulin antibodies with RIA (CisBiointernational, 
France). The cut-off values for ICA, GADA and IA2A 
positivity were 10 Juvenile Diabetes Foundation units, 
10 U/mL, and 20 U/mL respectively. According to the 
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caemia 6.11 mmol/L (normal 3.3–5.9 mmol/L). The glu-
cose level of 12 mmol/L in 120’ during oral glucose toler-
ance test (OGTT) confirmed the diagnosis of diabetes. 
The level of HbA1c at the time of admission was 5.91% 
(normal range 4.8–6.0). Fasting hyperinsulinaemia and 
insulin level at 120 minutes of OGTT was 101.7 uU/mL, 
indicating insulin resistance (insulin level at 120 minutes 
> 75 uU/mL) [6, 7]. This, however, was not confirmed by 
the HOMA-IR (Homeostasis model assessment insulin 
resistance) of 2.88, which was calculated by dividing 
the basal insulin (microunits per millilitre) and basal 
glucose (millimoles per litre) by 22.5 [8, 9]. The patient’s 
C-peptide production was normal. Islet-cell antibodies 
(ICA), GAD (glutamic acid carboxylase) antibodies, and 
protein tyrosine phosphatase antibodies (IA2) were 
negative. Other laboratory tests revealed the presence 
of proteinuria, hyperuricemia, hypomagnesemia and 
dyslipidemia (hypercholesterolemia, high level of LDL 
cholesterol) (Table I). Ultrasound examination of the 
abdomen revealed the presence of multiple cortical 
cysts in both of his kidneys. His glomerular filtration 
rate (GFR) was normal. He had no signs of retinopathy 
or other vision distortion. The co-existence of diabetes, 
hypertension, overweight, hyperuricemia and hy-
pertriglyceridemia was consistent with the diagnosis 
of metabolic syndrome. The child was initiated on 
treatment with metformin and ramipril. However, 
taking into account the co-existence of diabetes and 
congenital anomalies of the urinary tract, as well as 
the autosomal dominant history of diabetes in the 
family, the suspicion of HNF1B-MODY was worth 
considering.
Genetic findings
The promoters and 9 exons of HNF1B gene were 
sequenced and revealed that the patient was het-
erozygous for a novel Q248X mutation (nucleotide C 
to T transition at position 742 of the exon 3 of HNF1B 
gene) according to reference sequence NM_000458). 
Due to the positive family history, a genetic evalua-
tion was also performed in five family members of 
the proband — the proband’s sister, father and two 
male cousins. All of them, except the proband’s sister, 
were shown to be heterozygous for the same muta-
tion of the HNF1B gene.
Family members
The patient’s father (II-1), aged 37, had been diagnosed 
with Latent Autoimmune Diabetes of Adulthood (LADA) 
at the age of 36 (i.e. a year before his son’s diagnosis) 
and was treated with insulin. He was admitted to hos-
pital with hyperosmolar non-ketosis diabetes syndrome 
(HNKDS), blood glucose 1,065 mg/dL (59.1 mmol/L), 
and neurologic symptoms. His C-peptide plasma 
Table I. Summary of clinical features of the affected family members
Tabela I. Cechy fenotypowe I profil biochemiczny pacjentów z mutacją Q248X w genie HNF1B
Patient No III-1 III-3 III-4 II-1 II-3 I-2
Genetic status N/M N/M N/M N/M ? ?
Present age 13 10 8 37 36 57
 Age at diagnosis 13 10 8 36 34 33
BMI at diagnosis (kg/m2) 24.5 19.6 16.9 25.9 23.5 33.5
BMI at diagnosis (Z-score) 1.41 0.93 0.17 
Pancreas structure (CT) partial agenesis partial agenesis ? ?  ?
Liver structure (USG) normal normal normal normal normal –
Diabetes + – – + + +
Hypertension + non–dipper – +  – + 
Kidney structure cysts bilateral cortical 
cysts hydronephrosis
single hypoplastic 
ectopic cortical 
cysts
kidney cortical 
cysts
bilateral cortical 
cortical cysts
bilateral cortical 
cyst
single left kidney 
renal stone
Genitourinary tract PUV abnormalities 
UJO
UJO  – – – –
Spleen size (USG/CT) normal splenomegaly* splenomegaly* normal normal normal
Skeletal abnormalities spina bifida occulta* pectus carinatum*  – – – –
Eye defects  – –  – – early cataracts early cataracts
Other features short stature
PUV — posterior urethral valves; UJO — uretheropelvic junction obstruction; * new phenotypic feature
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concentration was within normal values. He was ICA 
and anti-GAD negative, but he was positive for IA2/
ICA512 antibodies 45.04 U/mL (N < 20 U/mL). He was 
overweight and suffered from hypertension. He also 
had hypercholesterolaemia, hypertriglyceridemia, 
hyperuricemia and elevated concentrations of alanine 
aminotransferase (ALT) and proteinuria. At the time 
of his hospitalisation, ultrasonography revealed sev-
eral cortical cysts in his kidneys — the largest of 4.7 
cm diameter. GFR of 51 mL/1.73 m2 indicating stage 3 
chronic kidney disease was also revealed. 
The proband’s uncle (father’s brother — II-3) 
aged 36, had initially been diagnosed with mild 
diabetes at the age of 34. Unlike his brother, he was 
lean and, until HNF1B-MODY diagnosis, treated with 
sulphonylurea. He had suffered from vision impair-
ment since early childhood caused by bilateral cata-
racts. He had elevated aminotransferases without any 
other signs of liver dysfunction and slightly increased 
serum amylase. At the time of diagnosis, abdominal 
ultrasonography did not confirm any anomalies. 
However, five years later, he presented with multiple 
small cortical cysts in both kidneys. He was negative 
for ICA, anti-GAD, IA2/ICA512 antibodies and had 
a normal value of C-peptide plasma concentration. 
Due to the suspicion of HNF1B-MODY in this family, 
both his sons aged 11 and eight years (i.e. the index 
subject’s two cousins) were invited for clinical evalu-
ation. Until the day of examination, they had been 
both thought to be healthy, except for a history of 
atopic diseases in the elder and episodes of enuresis 
in the younger one. Interestingly, in both of them 
splenomegaly was detected.
The proband’s cousin (III-3), aged 11, had pectus 
carinatum. Ultrasound examination revealed the pres-
ence of a single (right) kidney with hydronephrosis 
resulting from ureteropelvic junction obstruction. His 
left kidney was detected renoscintigraphically as a 
small hypoplastic formation of almost no function. He 
had proteinuria, but glomerular filtration rate (GFR) re-
mained normal. He also exhibited hyperbilirubinemia, 
and elevated aminotransferases.
The proband’s younger cousin (III-4), aged eight, 
was also diagnosed with multiple cysts of maximal 
diameter 4.3 mm in the right kidney. The left kidney 
was found to be ectopic and hypodysplastic (small with 
multiple cysts). He had hypercholesterolaemia with a 
high LDL cholesterol level and elevated serum amylase 
and aminotransferases. OGTT performed in both broth-
ers showed increased blood glucose concentrations of 
over 11.1 mmol/L (200 mg/dL) at 30 and 60 minutes 
of the test, but the results did not meet the criteria for 
diabetes at 0 and 120 minutes. The proband’s paternal 
grandmother (I-2), aged 57, was obese, short-statured 
(147 cm), and had suffered from a brittle diabetes since 
she was 33, treated with insulin. She died suddenly 
from cardiac infarction at the age of 57. The woman was 
reported to have had bilateral cataracts since childhood, 
cardiac arrhythmia, dyslipidemia, hypertension, one 
renal cyst of 23 mm diameter and one non-obstructing 
renal stone in her left kidney. She had seven siblings. 
Two of her sisters (one of whom was her monozygotic 
twin sister) were also reported to be diabetic. Diabetes 
was also present in the offspring (son) of the other sister.
The second proband’s uncle (father’s brother, 
II-5), aged 28, was born prematurely in the sixth 
Figure 1. Pedigree of a Polish family with Q248X mutation. The index subject (III-1) is indicated with an arrow. Black squares represent 
symptomatic family members. Asterisks denote individuals from whom DNA was obtained. N/M — heterozygous mutation carrier, 
N/N — both normal alleles
Rycina 1. Drzewo genealogiczne polskiej rodziny z mutacją Q248X. Strzałka wskazuje pacjenta III-1. Czarne kwadraty oznaczają 
pacjentów z objawami choroby. Gwiazdki wskazują członków rodziny, od których uzyskano DNA. N/M — heterozygotyczny nosiciel 
mutacji, N/N — obydwa allele prawidłowe
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month of pregnancy, with a birth weight of 1,080 g. 
He is physically and mentally disabled, very obese, 
and suffers from glaucoma. He has no diabetes so far. 
The proband’s younger sister (III-2) aged six, and his 
mother (II-2) are healthy. Interestingly, the younger 
sister was found to be positive for ICA (20 JDF). The 
clinical characteristics of the affected family members 
are summarised in Table I.
Further evaluation of paediatric mutation carriers 
Contrast-enhanced computed tomography (CT) of the 
abdomen was performed in the proband (III-1) (Fig. 
2) and the proband’s cousin (III-3). It revealed spleno-
megaly and complete absence of neck, body and tail of 
the pancreas with a normal-appearing head, indicating 
partial agenesis of the pancreas in both of the patients. 
The proband’s faecal elastase concentration was 
diminished (169 µg/g, normal range > 200 µg/g), while 
that of subject III-3 was normal (405 µg/g). 
Due to the rapidly deteriorating renal function of 
patient III-4 (presently stage 3 of chronic kidney failure), 
a contrast-enhanced CT was not carried out. Never-
theless, partial pancreatic agenesis is also probable in 
this case as only the presence of the head and body of 
pancreas was confirmed on ultrasonography.
Discussion
To date, there have been more than 100 different muta-
tions in HNF1B reported to cause HNF1B-MODY. They 
are either novel monoallelic mutations within or allelic 
deletions of chromosome 17q12 including the HNF1B 
locus (17cen-q21.3) [1,10]. The associated phenotypes 
result from altered expression pattern of the transcrip-
tion factor HNF1beta during organogenesis in utero [11]. 
We here report on a novel nonsense Q248X muta-
tion of the HNF1B gene found in four members of one 
family. This novel mutation, resulting in stop codon 
formation in exon 3, is associated with severe pheno-
typic features such as partial pancreatic agenesis, severe 
renal and urinary tract malformations, diabetes, liver 
disease, short stature, and cataracts. All of these have 
been previously reported in the literature in association 
with other mutations [5, 12–20]. 
However, in some members of the family, we also 
found new and interesting features such as spina bifida 
Table II. Synopsis of biochemical profile of patients with a Q248X mutation in the HNF1B gene
Tabela II. Cechy fenotypowe I profil biochemiczny pacjentów z mutacją Q248X w genie HNF1B
Patient No III-1 III-3 III-4 II-1 II-3 I-2 Ref. values
Genetic status N/M N/M N/M N/M ? ?
HbA1c at diagnosis (%) 5.91 4.95 5.12 12.1 11.3 7.2 4.8–6.0
 C–peptide fasting [ng/mL] 1.41 2.05 1.86 1.43 2.2 1.92 1.1–4.4
 C–peptide in 6’ [ng/mL]* 3.31 4.27 3.13 – 4.16 – 
AST [U/L] 33 77 87 24 53 15 10–37
ALT [U/L] 41 61 80 76 91 19 10–31
Total bilirubin [mg/dL] 0.37 1.48 0.4 0.8 0.65 0.2 <1.2
Total cholesterol [mg/dL] 194 153 209 204 176 226 130–200
HDL cholesterol [mg/dL] 55 60 81 46 – 67 35–80
LDL cholesterol [mg/dL] 133 87 120 130 – 150 50–130
VLDL cholesterol [mg/dL] 6 6 8 28 – 9 0–45
Triglycerides [mg/dL] 137 95 56 183 61 29 65–150
Serum amylase [U/L] 87 55 119 57 102 – 28–100
Urine amylase [U/L] 132 67 151 35 257 – 1–460
Blood urea nitrogen [mg/dL] 9 14 22 34 14 43 9–22
Serum creatinine [mg/dL] 0.51 0.53 0.72 1.7 1 1.27 0.4–1.2
GFR [ml/1,73 m2] 187 157 98 51 187 46.1
Proteinuria [mg/24h] 554 457 51 269 – 121 1### 
Uric acid [mg/dL] 9.7 5.6 6.1 8.7 5.2 7.2 2.1–7.0 
Magnesium [mEq/L] 0.96 1.24 1.3 – – – 1.3–2.1
*after intravenous glucagon 
1 ### 4–10y: 26–94 mg/24h; 10–16y: 29–238 mg/24h; adults: 45.0–75 mg/24h
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occulta, pectus carinatum, and enlarged spleen, which 
to the best of our knowledge have not been previously 
reported in patients with HNF1B-MODY. One could 
argue that spina bifida occulta is not that uncommon 
in the general population, so it cannot be excluded that 
this finding is a coincidence. 
However, the fact that another Q248X mutation 
carrier has pectus carinatum strengthens the chance 
that these changes could also be attributable to a mu-
tation in the HNF-1B gene. Recently, Dubois-Laforgue 
et al. found the presence of another chest abnormality 
— pectus excavatum — in 6/59 patients with MODY5 
(due to both an HNF1B point mutation and an HNF1B 
deletion), giving a higher prevalence of pectus excava-
tum among patients with MODY5 than in the general 
population [21]. Intriguingly, searching in the literature 
we encountered a report from 1979 describing an adult 
with a similar to our proband’s phenotype — a patient 
with diabetes, agenesis of the dorsal pancreas, and 
spina bifida [22]. 
Theoretically, together with spina bifida, chest 
abnormalities could result from altered HNF1B ex-
pression during embryonic development and growth 
of the skeleton and neural tube. HNF1B is expressed 
during morphogenesis of several tissues and organs 
including human trabecular bones of iliac crest and 
lumbar spinal laminae [23]. Moreover, HNF1B is 
required, directly or indirectly, for the activation of 
other transcription factors and their target genes [24]. 
Nevertheless, the precise role of HNF1B at different 
timings and in different compartments of skeleton has 
not been yet elucidated.
Splenomegaly as a symptom related to HNF1B de-
fect is also probable, as HNF1B is expressed in the spleen 
and lymphoid tissue [23]. Hypothetically, it could also 
be associated with abnormal liver development as it 
is seen in ciliopathy-associated liver diseases without 
signs of hypersplenism until adulthood [25]. 
Short stature and eye defects (such as coloboma, 
glaucoma or bilateral cataracts at onset of diabetes) have 
been previously described, but referred to HNF1B-dele-
tion syndrome due to heterozygous interstitial micro-
deletion on chromosome 17q12, leading to monoallelic 
loss of HNF1B [1]. In the family investigated by us, two 
members reported having had cataracts since child-
hood, years before their diabetes had been diagnosed.
Phenotypes of family members sharing this muta-
tion are highly variable, which is especially seen in cases 
of kidney and urinary tract defects, ranging from the 
presence of only a single cortical cyst in patient I, pos-
terior urethral valves, congenital ureteropelvic junction 
obstruction and bilateral cortical cysts in the proband, 
to hypodysplastic, ectopic solitary kidney and rapidly 
deteriorating chronic kidney disease seen in the young-
est patients. Such interfamilial variability of the pheno-
type in patients who harboured the same mutation in 
HNF1B has also been reported by other authors [12]. 
The diabetic phenotypes of affected family members 
are also variable, which suggests incomplete genetic 
penetrance. The proband was diagnosed with diabetes 
in his puberty and his overweight, hypertension, hyper-
insulinemia, dyslipidemia and hyperuricemia were at 
first ascribed to metabolic syndrome. After three years 
of follow-up, his blood sugar is well controlled with 
metformin and diet (HbA1c 5.7%), although a gradual 
decrease in C-peptide concentration after stimulation 
with glucagon indicates that future insulin therapy 
might be necessary. CT scan of abdomen revealed 
partial pancreatic agenesis.
In his adult relatives, diabetes was discovered in 
their thirties, with high HbA1c and normal C-peptide 
levels. Subject II-1 was positive for IA2 antibodies, 
which suggests that he might also have mild autoim-
mune diabetes in addition to HNF1B-MODY. 
Growing evidence suggests that autoantibodies are 
present in monogenic forms of diabetes. For example, 
a quarter of the patients with MODY examined by 
Urbanová et al. were positive for GAD or IA-2 au-
toantibodies [26]. The severe onset of his diabetes as 
hyperosmolar non-ketotic diabetes syndrome (HNKDS) 
indicates that the amounts of insulin present in some 
patients with this type of diabetes are sufficient to sup-
press ketogenesis. The concurrence of two different 
types of diabetes may also explain the deteriorated 
Figure 2. Axial CT image of the index subject shows multiple 
cortical cysts in both kidneys, the pancreatic head but the absence 
of the corpus and tail of the pancreas
Rycina 2. Badanie tomograficzne jamy brzusznej (przekrój osiowy) 
jamy brzusznej pacjenta (III-1) ukazujący wielotorbielowatość 
nerek oraz obecność jedynie głowy trzustki
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metabolic control in this patient (HbA1c value 12.1%). 
The mechanisms by which mutations in the HNF1B 
gene cause diabetes mellitus are still not well under-
stood, and might include partial agenesis of the pan-
creas, abnormal pancreatic islet development during 
faetal life thereby limiting their later function, as well as 
impaired transcriptional regulation of genes that play 
a key role in normal pancreatic beta cell function [27, 28]. 
Interestingly, insulin resistance is common even among 
not overweight HNF1B-MODY patients [1]. Likewise, 
the mechanisms underlying the phenotypic variability 
among diabetic HNF1β-mutant carriers, within and 
between families, are presently unknown.
Conclusion
HNF1B-MODY is not just a renal cyst and diabetes 
syndrome (RCAD) [20], but a multi-organ disorder 
with different symptoms and disease profile. We found 
a novel Q248X mutation in the HNF1B gene responsible 
for severe phenotypes and probably some new clinical 
features such as spina bifida occulta, pectus carinatum, 
and splenomegaly. 
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